The Global Stem Cell Therapy Market is set to witness a healthy growth rate of 20% by 2029. A favorable investment ...

The advent of induced pluripotent stem cells (iPSCs) could be key to addressing this challenge, with iPSCs offering the potential for self-renewal and pluridirectional differentiation. iPSCs can ...

Stem cell therapy shows early promise for treating Parkinson's. Discover who is in the race to bring this breakthrough to ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

With its wealth of experience, Creative Biolabs stands ready to support global researchers in advancing their iPSC-derived cell therapy studies.

successfully established cultures of naive-type induced pluripotent stem cells from chimpanzee somatic cells. Not only did they reveal key insights into the mechanisms necessary for self-renewal ...

Japan has made regenerative medicine a priority. It was the first country to approve clinical use of iPS cells, and it ...

Investors now have three ASX-listed stem cell therapy companies to choose from – and we can thank Mesoblast for inspiring the third.

Embryonic stem cells and induced pluripotent stem cells are pluripotent stem cells. Brain tissue mechanics influence development and disease. Here, the authors show that LIS1 mutations increase ...

Discover how induced pluripotent stem cell technology is solving scale and consistency issues in mesenchymal stem/stromal ...

CRISPR-edited iPSCs uncover early mitochondrial defects shared across ALS mutations, revealing pathways that could guide future treatments.